These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22388022)

  • 1. Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?
    Chan FK
    Am J Gastroenterol; 2012 Mar; 107(3):387-8. PubMed ID: 22388022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers.
    Laine L; Kivitz AJ; Bello AE; Grahn AY; Schiff MH; Taha AS
    Am J Gastroenterol; 2012 Mar; 107(3):379-86. PubMed ID: 22186979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
    Bello AE; Kent JD; Holt RJ
    Phys Sportsmed; 2015 Jul; 43(3):193-9. PubMed ID: 26165391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fixed-dose combination ibuprofen and famotidine (Duexis).
    Med Lett Drugs Ther; 2011 Oct; 53(1376):85-6. PubMed ID: 22033211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
    Bello AE; Kent JD; Grahn AY; Rice P; Holt RJ
    Postgrad Med; 2014 Jul; 126(4):82-91. PubMed ID: 25141246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.
    Deeks ED
    Clin Drug Investig; 2013 Sep; 33(9):689-97. PubMed ID: 23881568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.
    Kuan R; Holt RJ; Johnson KE; Kent JD; Peura DA; Malone D
    Clin Ther; 2013 Mar; 35(3):321-32. PubMed ID: 23497762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
    Taha AS; Hudson N; Hawkey CJ; Swannell AJ; Trye PN; Cottrell J; Mann SG; Simon TJ; Sturrock RD; Russell RI
    N Engl J Med; 1996 May; 334(22):1435-9. PubMed ID: 8618582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.
    La Corte R; Caselli M; Castellino G; Bajocchi G; Trotta F
    Drug Saf; 1999 Jun; 20(6):527-43. PubMed ID: 10392669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of NSAID induced gastroduodenal ulcers].
    Hansen JM; Bytzer P
    Ugeskr Laeger; 2001 Oct; 163(44):6103-5. PubMed ID: 11715151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fixed dose combination of ibuprofen and famotidine.
    Birk JW; Myers M
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1385-91. PubMed ID: 19659445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.
    Tuskey A; Peura D
    Arthritis Res Ther; 2013; 15 Suppl 3(Suppl 3):S6. PubMed ID: 24267478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
    Ogawa N
    Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy.
    Yeomans ND
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S89-92. PubMed ID: 10379475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drug to prevent NSAID-related ulcers.
    Liss GM
    CMAJ; 1996 Oct; 155(8):1043. PubMed ID: 8873631
    [No Abstract]   [Full Text] [Related]  

  • 17. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
    Schiff M; Peura D
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):25-35. PubMed ID: 22149579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.
    Hudson N; Taha AS; Russell RI; Trye P; Cottrell J; Mann SG; Swanell AJ; Sturrock RD; Hawkey CJ
    Gastroenterology; 1997 Jun; 112(6):1817-22. PubMed ID: 9178671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Present position in the prevention and therapy of NSAID-induced ulcers].
    Lehmann FS; Beglinger C
    Schweiz Med Wochenschr; 1999 Jul; 129(29-30):1073-80. PubMed ID: 10464910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug.
    Bello AE
    Ther Adv Musculoskelet Dis; 2012 Oct; 4(5):327-39. PubMed ID: 23024710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.